TY - JOUR
T1 - Analysis of Pharmacokinetics in the Cochlea of the Inner Ear
AU - Sawamura, Seishiro
AU - Ogata, Genki
AU - Asai, Kai
AU - Razvina, Olga
AU - Ota, Takeru
AU - Zhang, Qi
AU - Madhurantakam, Sasya
AU - Akiyama, Koei
AU - Ino, Daisuke
AU - Kanzaki, Sho
AU - Saiki, Takuro
AU - Matsumoto, Yoshifumi
AU - Moriyama, Masato
AU - Saijo, Yasuo
AU - Horii, Arata
AU - Einaga, Yasuaki
AU - Hibino, Hiroshi
N1 - Funding Information:
This work is supported by the following research grants and funds: AMED-CREST JP20gm0810004 (to HH) from AMED, Grant-in-Aid for Young Scientists 20K16005 (to SS), Grant-in-Aid for Scientific Research B 18H03513 (to GO), Grant-in-Aid for Young Scientists 19K16442 (to RO), Grant-in-Aid for Young Scientists 19K16826 (to YM), Grant-in-Aid for Scientific Research C 20K07842 (to MM), Grant-in-Aid for Scientific Research A 18H04062 (to HH), and Grant-in-Aid for Challenging Exploratory Research 20K21883 (to HH) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Publisher Copyright:
© Copyright © 2021 Sawamura, Ogata, Asai, Razvina, Ota, Zhang, Madhurantakam, Akiyama, Ino, Kanzaki, Saiki, Matsumoto, Moriyama, Saijo, Horii, Einaga and Hibino.
PY - 2021/5/3
Y1 - 2021/5/3
N2 - Hearing loss affects >5% of the global population and therefore, has a great social and clinical impact. Sensorineural hearing loss, which can be caused by different factors, such as acoustic trauma, aging, and administration of certain classes of drugs, stems primarily from a dysfunction of the cochlea in the inner ear. Few therapeutic strategies against sensorineural hearing loss are available. To develop effective treatments for this disease, it is crucial to precisely determine the behavior of ototoxic and therapeutic agents in the microenvironment of the cochlea in live animals. Since the 1980s, a number of studies have addressed this issue by different methodologies. However, there is much less information on pharmacokinetics in the cochlea than that in other organs; the delay in ontological pharmacology is likely due to technical difficulties with accessing the cochlea, a tiny organ that is encased with a bony wall and has a fine and complicated internal structure. In this review, we not only summarize the observations and insights obtained in classic and recent studies on pharmacokinetics in the cochlea but also describe relevant analytical techniques, with their strengths, limitations, and prospects.
AB - Hearing loss affects >5% of the global population and therefore, has a great social and clinical impact. Sensorineural hearing loss, which can be caused by different factors, such as acoustic trauma, aging, and administration of certain classes of drugs, stems primarily from a dysfunction of the cochlea in the inner ear. Few therapeutic strategies against sensorineural hearing loss are available. To develop effective treatments for this disease, it is crucial to precisely determine the behavior of ototoxic and therapeutic agents in the microenvironment of the cochlea in live animals. Since the 1980s, a number of studies have addressed this issue by different methodologies. However, there is much less information on pharmacokinetics in the cochlea than that in other organs; the delay in ontological pharmacology is likely due to technical difficulties with accessing the cochlea, a tiny organ that is encased with a bony wall and has a fine and complicated internal structure. In this review, we not only summarize the observations and insights obtained in classic and recent studies on pharmacokinetics in the cochlea but also describe relevant analytical techniques, with their strengths, limitations, and prospects.
KW - cochlea
KW - ototoxic drug
KW - pharmacokinetics
KW - real-time measurement
KW - sensorineural hearing loss
KW - therapeutic reagent
UR - http://www.scopus.com/inward/record.url?scp=85106057264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106057264&partnerID=8YFLogxK
U2 - 10.3389/fphar.2021.633505
DO - 10.3389/fphar.2021.633505
M3 - Review article
AN - SCOPUS:85106057264
SN - 1663-9812
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 633505
ER -